Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8999208 | 0.93 | NPC1 (0.50) | MEN1KMT2ANPC1MAPTALDH1A1 | |
| SCHEMBL8999201 | 0.93 | NPC1 (0.50) | MEN1KMT2ANPC1MAPTALDH1A1 | |
| SCHEMBL6338797 | 0.92 | L3MBTL1 (0.50) | MEN1KMT2ANPC1MAPTALDH1A1 | |
| SCHEMBL5500811 | 0.92 | L3MBTL1 (0.50) | MEN1KMT2ANPC1MAPTALDH1A1 | |
| SCHEMBL5500812 | 0.92 | L3MBTL1 (0.50) | MEN1KMT2ANPC1MAPTALDH1A1 | |
| SCHEMBL433413 | 0.92 | ESR1 (0.53) | MEN1KMT2ANPC1MAPTALDH1A1 | |
| SCHEMBL433415 | 0.92 | ESR1 (0.53) | MEN1KMT2ANPC1MAPTALDH1A1 | |
| SCHEMBL1744974 | 0.91 | NPC1 (0.48) | MEN1KMT2ANPC1MAPTALDH1A1 | |
| SCHEMBL1744978 | 0.91 | NPC1 (0.48) | MEN1KMT2ANPC1MAPTALDH1A1 | |
| SCHEMBL1744976 | 0.91 | NPC1 (0.48) | MEN1KMT2ANPC1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953256-B2 | Composition comprising fluorine-containing ketone | SINOCHEM LANTIAN CO., LTD (CN) | 2021-03-23 | — | — | US | claimed |
| EP-3421105-A1 | COMPOSITION COMPRISING FLUORINE-CONTAINING KETONE | Sinochem Lantian Co., Ltd. (CN) | 2019-01-02 | — | — | EP | claimed |
| US-20180200553-A1 | COMPOSITION COMPRISING FLUORINE-CONTAINING KETONE | SINOCHEM LANTIAN CO., LTD (CN) | 2018-07-19 | — | — | US | claimed |
| WO-2022255228-A1 | COMPOSITION, CURED PRODUCT OR COMPACT, OPTICAL MEMBER, AND LENS | 富士フイルム株式会社 | 2022-12-08 | — | — | WO | disclosed |
| US-11485725-B2 | Derivatives of piperlongumine and uses thereof | AURANSA INC. (US) | 2022-11-01 | — | — | US | disclosed |
| CN-113233980-B | Synthesis method of beta-chloroacid ester and alpha, beta-unsaturated acid ester compound | 台州学院 | 2022-04-05 | — | — | CN | disclosed |
| EP-3886633-A1 | CUSHIONING ELEMENT UTILIZING FOAM PARTICLES | NIKE Innovate C.V. (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-113233980-A | Synthesis method of beta-chloroacid ester and alpha, beta-unsaturated acid ester compound | 台州学院 | 2021-08-10 | — | — | CN | disclosed |
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2021-07-01 | — | — | US | disclosed |
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2021-07-01 | — | — | US | disclosed |
| EP-3836816-A1 | FOOTWEAR SOLE STRUCTURE HAVING A COMPOSITE ELEMENT AND METHODS FOR MANUFACTURING SAME | NIKE Innovate C.V. (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-0785926-A1 | NEW CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1997-07-30 | — | — | EP | disclosed |
| US-5559109-A | Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist | SANKKO COMPANY, LIMITED (JP) | 1996-09-24 | — | — | US | disclosed |
| US-5556852-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| WO-1996011914-A1 | NEW CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1996-04-25 | — | — | WO | disclosed |
| US-5442071-A | Photostability | CIBA-GEIGY CORPORATION (US) | 1995-08-15 | — | — | US | disclosed |
| US-5369106-A | N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists | SANKYO COMPANY, LIMITED (JP) | 1994-11-29 | — | — | US | disclosed |
| US-5192766-A | Platelet activating factor antagonist | SANKYO COMPANY, LIMITED (JP) | 1993-03-09 | — | — | US | disclosed |
| US-4595532-A | N-(substituted-methyl)-azetidin-2-ones | UNIVERSITY OF NOTRE DAME DU LAC (US) | 1986-06-17 | — | — | US | disclosed |
| EP-0116432-A2 | Improvements in or relating to N-(substituted-methyl)-azetidin-2-ones | THE UNIVERSITY OF NOTRE DAME DU LAC (US) | 1984-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | THPO, PIR, PAK6 | MEN1 1394/4885KMT2A 2507/4885NPC1 868/4885 |
| US-11485725-B2 | Derivatives of piperlongumine and uses thereof | PIR, THPO, DHPS | MEN1 1372/4885KMT2A 2612/4885NPC1 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.